A recent study has demonstrated that the long non-coding RNA VPS9D1-AS1 is highly expressed in colorectal cancer and predicts poor prognosis. However, role of VPS9D1-AS1 in gastric cancer remained poorly understood. OBJECTIVE: The aim of this study is to decipher the expression of VPS9D1-AS1 in gastric cancer (GC) patients, so as to assess whether or not it could be used as a novel biomarker for prognosis in gastric cancer patients. METHODS: The expression of VPS9D1-AS1 was examined in cancer tissues and paired adjacent non-tumorous tissues from 126 gastric cancer patients using qRT-PCR. Correlations between the expression of VPS9D1-AS1 and clinicopathological parameters and patients' survival were analyzed. RESULTS: VPS9D1-AS1 expression was downregulated in gastric cancer tissues than that in adjacent non-tumorous tissues (P < 0.001). VPS9D1-AS1 expression level was markedly correlated with tumor size and TNM stage in gastric cancer. KaplanMeier analysis showed low expression of VPS9D1-AS1 were correlated with poor overall and disease free survival. On multivariate analysis, the hazard ratio of VPS9D1-AS expression was 0.30 (95% CI = 0.13-0.66, P = 0.003) for overall survival. CONCLUSIONS: Overall, our data suggest that downregulated VPS9D1-AS1 may be used as a novel prognosis predictor of gastric cancer.
cause more than half of patients have stepped into a 8 progressive stage at diagnosis [3, 4] . The 5-year over-9 all survival rate of GC patients is estimated to be less 10 than 30% [1, 4] . It is thus urgent to find novel molecular 11 biomarkers for diagnosis and treatment of GC.
12
Recently, development in sequencing technology 13 and bioinformatics has contributed to the findings that 14 the vast majority of human genomes are actively tran-15 scribed into non-coding RNAs without protein cod-16 ing potentials [5, 6] , which are classified into long non-17 coding RNAs (lncRNAs) and small non-coding RNAs 18 such as microRNAs according to their lengths [7] . Pre-19 vious studies have revealed that microRNAs play im-20 portant roles in cancer development [8] (Tumor/Normal) < 0) was found in 74.60% of GC pa-126 tients in our cohort (Fig. 1B) cancer cells compared with that in GES1 cell (Fig. 1C) . expression arm (expression of VPS9D1-AS1 above 138 the cutoff, n = 32) and low expression arm (ex-139 pression of VPS9D1-AS1 below the cutoff, n = 94) 140 (Fig. 1B) To further explore whether VPS9D1-AS1 expres-157 sion predicted prognosis of GC patients, we used 158 Kaplan-Meier methods with log-rank tests. As shown 159 in Fig. 3A , the median overall survival of patients with 160 low VPS9D1-AS1 expression was significantly shorter 161 u n c o r r e c t e d p r o o f v e r s i o n and are proposed to be diagnostic markers or therapeu-189 tic targets of human cancer [22] [23] [24] .
Results
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Over the past decades, the possible molecular al-191 terations underlying gastric carcinogenesis have been 192 thoroughly explored [25, 26] 
